Plerixafor for Autologous Peripheral Blood Stem Cell Mobilization in Patients Previously Treated with Fludarabine or Lenalidomide
Florent Malard(Sorbonne Université), Rafael F. Duarte(Institut Català d'Oncologia), Roberto M. Lemoli(University of Genoa), Nina Worel(Medical University of Vienna), Mohamad Mohty(Inserm), Francesco Lanza(Ospedale "Santa Maria delle Croci" di Ravenna), Kenneth Douglas(Beatson West of Scotland Cancer Centre), Dominik Selleslag(National Institutes of Health), Zdeněk Kořı́stek(University of Ostrava), Grzegorz Basak(Medical University of Warsaw), Gábor Mikala(Unified Szent István and Szent László Hospital), Jane F. Apperley(Hammersmith Hospital), Ozren Jakšić(University of Zagreb), Kai Hübel(University Hospital Cologne), Nicolaus Kröger(Universität Hamburg), Ian H Gabriel(Imperial College London), Catarina Geraldes(Hospitais da Universidade de Coimbra)
Cited by 44
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Defining Opportunistic Invasive Fungal Infections in Immunocompromised Patients with Cancer and Hematopoietic Stem Cell Transplants: An International Consensus
|Clinical Infectious Diseases|2002|2.3k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2017|1.2k
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
|New England Journal of Medicine|2020|859